🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
REGN
NASDAQ
🇺🇸 US
Regeneron Pharmaceuticals
Pharmaceuticals
18Score
DipBuster Score™
$793.26
$14.39 (-1.78%)
Live price · Source: Yahoo
52-Week Position
$541.00
79% of range
$859.34
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
BetaN/A
52W High$859.34
52W Low$541.00
DipBuster Brief
Key signals at a glance
Zone: Consider Trimming
Neutral
Mid-Range Position (79% of 52-Week Range)
The stock sits in the middle of its annual range — no extreme dip opportunity, but also not overextended.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt CapN/A
52W Position79% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta—
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at Regeneron Pharmaceuticals (REGN), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-08-10 | Guarini Kathryn | SELL | 400 |
| 2026-08-10 | Guarini Kathryn | SELL | 400 |
| 2026-08-10 | Guarini Kathryn | BUY | 400 |
| 2026-08-10 | Zoghbi Huda Y | SELL | 800 |
| 2026-08-10 | Zoghbi Huda Y | SELL | 800 |
| 2026-08-10 | Zoghbi Huda Y | BUY | 800 |
| 2026-07-02 | Ryan Arthur F | SELL | 200 |
| 2026-05-01 | Ryan Arthur F | SELL | 2 |
| 2026-05-01 | Ryan Arthur F | SELL | 1 |
| 2026-05-01 | Ryan Arthur F | SELL | 5 |
Graham NCAV Analysis
Above net-net level
Current Assets$18.02B
Less: Total Liabilities−$9.30B
= Net Current Asset Value$8.72B
NCAV Per Share$62.5468
Current Price$793.26
Price / NCAV12.68×
Margin of Safety-1168.3%
Computed from 2025-12-31 balance sheet (Yahoo Finance). NCAV = current assets − total liabilities. Verify against the latest report.
Valuation
P/E RatioN/A
Market CapN/A
BetaN/A
Dividend/yrNone
52W High$859.34
52W Low$541.00
52-Week Range
$541.00Now$859.34
79% through annual range
From 52W High−7.7%
From 52W Low+46.6%
📖 Plain English Summary
Regeneron Pharmaceuticals is at 79% of its 52-week range.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for REGN
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — REGN
Heuristic · balance sheet, insider filings, price data, academic research
Regeneron Pharmaceuticals — DipBuster Score 18/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track Regeneron Pharmaceuticals free
Add REGN to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Freetrade
Simple investing app. Free ISA. UK and US stocks. FCA regulated.
Free share when you fund your account
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
8/25
Momentum & Volume
5/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
22
/100 · NEUTRAL
dip depth
4/25
oversold rsi
4/25
mean reversion
14/15
insider zone
0/25
capitulation
0/10
Technical signal only. Not financial advice.
Quick Take
⚪
Not a Dip
DipBuster Score: 18/100
📊
Run a full check in the AI analysis tab for a deeper look.